ION464

Phase 1Small molecule

Ionis Pharmaceuticals

ION464 is one of 14 small molecule programs targeting Multiple System Atrophy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple System AtrophyRecruiting

Multiple System AtrophyPhase 1

Recruiting

Competition

Competitive Landscape

20 competitors in Multiple System Atrophy

#DrugCompanyPhaseTrials

Rifadin

Northera

Rilutek

AAzurity Pharmaceuticals

Sudafed

Lu AF95245

1 6

TEV-56286

Teva

Phase 2

2 7

Foralumab

TTiziana Life Sciences LTD

Phase 2

1 8

Bendopa

MMerz North America, Inc.

Preclinical

1 9

ATH434

AAlterity Therapeutics

Phase 2

2 10

ALT001

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Multiple System Atrophy

NCT04165486

Clinical

Trials by Indication[1]

Multiple System Atrophy1 trial

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

Recruiting· Ionis Pharmaceuticals logo

Ionis Pharmaceuticals·Phase 1·NCT04165486·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ION464. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ION464 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ION464. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ionis Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Ionis Pharmaceuticals

ION464

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Multiple System Atrophy1 trial

References

Drug Info

Quick Facts

Related News